ACRV
KPTI

Sharon Shacham

Known title: Chief Scientific OfficerCIK: 0001588438

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 15, 2026

Acrivon Therapeutics noted among health‑care stocks moving in after‑market. Acrivon Therapeutics (ACRV) was included in a Benzinga roundup of twelve health‑care stocks that showed price movement during Wednesday’s after‑market session. The mention signals recent trading activity after regular hours. The stock is currently near its 52‑week low and its RSI is below 40, suggesting limited momentum.

this person other insiders at ACRV

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 2, 2026

Karyopharm Reports Inducement Grant Under Nasdaq Rule. Karyopharm Therapeutics disclosed an inducement grant made under Nasdaq Listing Rule 5635(c)(4). This type of disclosure is typically required when a company offers equity compensation to a new employee or consultant to induce them to join the firm. The announcement is a standard corporate compliance update rather than a change in business operations or financial results.

this person other insiders at KPTI

Transaction History

ACRV▲ Buy$0
KPTI▲ Buy$0
KPTI▼ Sell$64K
KPTI▼ Sell$64K
KPTI▲ Buy$0
KPTI▼ Sell$110K
KPTI▼ Sell$110K
KPTI▼ Sell$66K
KPTI▼ Sell$67K

We use analytics to understand how market-wall is used. No personal data is sold.